Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
1.860
+0.110 (6.29%)
At close: Nov 3, 2026, 4:00 PM EST
1.751
-0.109 (-5.84%)
After-hours: Nov 3, 2026, 7:30 PM EST
Alaunos Therapeutics Employees
Alaunos Therapeutics had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Alaunos Therapeutics the 44,331st largest employer in the world and 7,627th in the United States.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,000
Profits / Employee
-$4,116,000
Market Cap
4.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2023 | 1 | -33 | -97.06% | 1 | 0 |
| Dec 31, 2022 | 34 | -7 | -17.07% | 34 | 0 |
| Dec 31, 2021 | 41 | -65 | -61.32% | 41 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| Longeveron | 38 |
| AIM ImmunoTech | 21 |
| Imunon | 20 |
| Cardio Diagnostics Holdings | 17 |
| Azitra | 13 |
| Traws Pharma | 7 |
| Can-Fite BioPharma | 5 |
TCRT News
- 21 days ago - Alaunos Therapeutics announces completion of Velaris acquisition - TheFly
- 21 days ago - Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics - GlobeNewsWire
- 21 days ago - Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc. - PRNewsWire
- 6 weeks ago - Alaunos Therapeutics prices 380,469 shares at $1.46 in registered direct offer - TheFly
- 6 weeks ago - Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules - GlobeNewsWire
- 2 months ago - Alaunos Therapeutics Quarterly report: Q2 2026 - Filings
- 5 months ago - Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies - TheFly
- 5 months ago - Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies - GlobeNewsWire